{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:12:57Z","timestamp":1793394777100,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK","award":["Study 221872"],"award-info":[{"award-number":["Study 221872"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory condition, often treated with oral corticosteroids (OCS). OCS overexposure can increase the risk of adverse effects, highlighting the need for better treatment strategies including timely biologic therapy use. This study explored OCS use patterns in patients with severe CRSwNP in Canada pre-biologic initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective, real-world study used IQVIA\u2019s Private Drug Plan (PDP) claims database to examine OCS use patterns 0\u201324\u00a0months pre-initiation of biologic therapy in patients with inferred CRSwNP in Canada (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009747). Outcomes included OCS use patterns (proportions, claims per patient and by prescribing physician specialty, overexposure [\u2265\u20091000\u00a0mg annually, prednisone-equivalent]), demographics, and stratified by comorbid asthma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 747 patients indexed from the PDP, 81.0% had\u2009\u2265\u20091 OCS claim(s), with a median (interquartile range [IQR]) of 3.0 (4.0) claims per patient. Median (IQR) total OCS dose over 24\u00a0months was 1020 (1420) mg; 41.5% of patients experienced OCS overexposure. OCS was primarily prescribed by general practitioners (35.9%) and otolaryngologists (32.8%). Patients had a median (IQR) age of 51 (18) years at index, 52.1% were male, and most were from Ontario (48.7%). OCS use was highest in patients with comorbid severe asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study highlights OCS overexposure in patients with CRSwNP pre-biologic initiation. Enhancing physician and patient awareness of appropriate OCS use and timely biologic initiation could reduce the risk of OCS-related adverse effects and improve CRSwNP management, benefiting long-term patient outcomes through shared decision-making.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      GSK study number 221872.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13223-025-00989-w","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:45:51Z","timestamp":1764859551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral corticosteroid overexposure: characterizing oral corticosteroid use in patients with chronic rhinosinusitis with nasal polypS in Canada (ACTIONS) results"],"prefix":"10.1186","volume":"21","author":[{"given":"Yvonne","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Corriveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koyo","family":"Usuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danya","family":"Thayaparan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juejing","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Thamboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"989_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","volume":"4","author":"WW Stevens","year":"2016","unstructured":"Stevens WW, Schleimer RP, Kern RC. Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2016;4:565\u201372.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"989_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.401","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58:1\u2013464.","journal-title":"Rhinology"},{"key":"989_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40463-017-0205-3","volume":"46","author":"BM Hanna","year":"2017","unstructured":"Hanna BM, Crump RT, Liu G, Sutherland JM, Janjua AS. Incidence and burden of comorbid pain and depression in patients with chronic rhinosinusitis awaiting endoscopic sinus surgery in Canada. J Otolaryngol Head Neck Surg. 2017;46:23.","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"989_CR4","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1080\/03007995.2020.1815682","volume":"36","author":"S Chen","year":"2020","unstructured":"Chen S, Zhou A, Emmanuel B, Thomas K, Guiang H. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020;36:1897\u2013911.","journal-title":"Curr Med Res Opin"},{"key":"989_CR5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/00005537-200307000-00016","volume":"113","author":"Y Chen","year":"2003","unstructured":"Chen Y, Dales R, Lin M. The epidemiology of chronic rhinosinusitis in Canadians. Laryngoscope. 2003;113:1199\u2013205.","journal-title":"Laryngoscope"},{"key":"989_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2500\/aap.2019.40.4182","volume":"40","author":"JN Palmer","year":"2019","unstructured":"Palmer JN, Messina JC, Biletch R, Grosel K, Mahmoud RA. A cross-sectional, population-based survey of U.S. adults with symptoms of chronic rhinosinusitis. Allergy Asthma Proc. 2019;40:48\u201356.","journal-title":"Allergy Asthma Proc"},{"key":"989_CR7","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638\u201350.","journal-title":"Lancet"},{"key":"989_CR8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.anai.2024.10.015","volume":"134","author":"JK Han","year":"2025","unstructured":"Han JK, Silver J, Dhangar I, Veeranki P, Deb A. Quantifying corticosteroid burden in chronic rhinosinusitis with nasal polyps: a retrospective US database study. Ann Allergy Asthma Immunol. 2025;134:685-693.e5.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"989_CR9","unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (2024 update). 2024. https:\/\/ginasthma.org\/2024-report\/. Accessed 21 March 2025."},{"key":"989_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/JAA.S176026","volume":"11","author":"DB Price","year":"2018","unstructured":"Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193\u2013204.","journal-title":"J Asthma Allergy"},{"key":"989_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40463-023-00626-9","volume":"52","author":"AV Thamboo","year":"2023","unstructured":"Thamboo AV, Lee M, Bhutani M, Chan C, Chan Y, Chapman KR, et al. Canadian multidisciplinary expert consensus on the use of biologics in upper airways: a Delphi study. J Otolaryngol Head Neck Surg. 2023;52:30.","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"989_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/alr.22264","volume":"9","author":"KA Smith","year":"2019","unstructured":"Smith KA, Orlandi RR, Oakley G, Meeks H, Curtin K, Alt JA. Long-term revision rates for endoscopic sinus surgery. Int Forum Allergy Rhinol. 2019;9:402\u20138.","journal-title":"Int Forum Allergy Rhinol"},{"key":"989_CR13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/jpm12060897","volume":"12","author":"E De Corso","year":"2022","unstructured":"De Corso E, Pipolo C, Cantone E, Ottaviano G, Gallo S, Canevari FRM, et al. Survey on use of local and systemic corticosteroids in the management of chronic rhinosinusitis with nasal polyps: identification of unmet clinical needs. J Pers Med. 2022;12:897.","journal-title":"J Pers Med"},{"key":"989_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13601-019-0303-6","volume":"10","author":"V Hox","year":"2020","unstructured":"Hox V, Lourijsen E, Jordens A, Aasbjerg K, Agache I, Alobid I, et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy. 2020;10:1.","journal-title":"Clin Transl Allergy"},{"issue":"Suppl. 65","key":"989_CR15","first-page":"PA3548","volume":"58","author":"LG Heaney","year":"2021","unstructured":"Heaney LG, Schleich F, Korn S, Howarth P, Antoun ZE, Bourdin A, et al. Recognising the long-term burden of short course oral corticosteroids. Eur Resp J. 2021;58(Suppl. 65):PA3548.","journal-title":"Eur Resp J."},{"key":"989_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2024.104596","volume":"46","author":"S Fujieda","year":"2025","unstructured":"Fujieda S, Pinto JM, Jang DW, Han JK, Mims J, De Corso E, et al. Baseline disease characteristics by surgery history among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the global AROMA registry. Am J Otolaryngol. 2025;46:104596.","journal-title":"Am J Otolaryngol"},{"key":"989_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13223-023-00823-1","volume":"19","author":"M Yong","year":"2023","unstructured":"Yong M, Kirubalingam K, Desrosiers MY, Kilty SJ, Thamboo A. Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada. Allergy Asthma Clin Immunol. 2023;19:90.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"989_CR18","unstructured":"Health Canada. Notice of compliance information: DUPIXENT. 2022. https:\/\/health-products.canada.ca\/noc-ac\/nocInfo?no=24044. Accessed 6 February 2025."},{"key":"989_CR19","unstructured":"Health Canada. Notice of compliance information: XOLAIR 2022. https:\/\/health-products.canada.ca\/noc-ac\/nocInfo?no=26290. Accessed 6 February 2025."},{"key":"989_CR20","unstructured":"Health Canada. Notice of compliance information: NUCALA. 2022. https:\/\/health-products.canada.ca\/noc-ac\/nocInfo?no=26988. Accessed 6 February 2025."},{"key":"989_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40463-022-00570-0","volume":"51","author":"SJ Kilty","year":"2022","unstructured":"Kilty SJ, Lasso A. Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps. J Otolaryngol Head Neck Surg. 2022;51:17.","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"989_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134374","volume":"12","author":"K Gerstacker","year":"2023","unstructured":"Gerstacker K, Ketterer MC, Jakob TF, Hildenbrand T. Real life observational study of treatment success of monoclonal antibodies for refractory chronic rhinosinusitis with nasal polyps. J Clin Med. 2023;12:4374.","journal-title":"J Clin Med"},{"key":"989_CR23","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/jpm12081304","volume":"12","author":"S Gallo","year":"2022","unstructured":"Gallo S, Castelnuovo P, Spirito L, Feduzi M, Seccia V, Visca D, et al. Mepolizumab improves outcomes of chronic rhinosinusitis with nasal polyps in severe asthmatic patients: a mutlicentric real-life study. J Pers Med. 2022;12:1304.","journal-title":"J Pers Med"},{"key":"989_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.480","volume":"145","author":"C Bachert","year":"2020","unstructured":"Bachert C, Gevaert P, Corren J, Mullol J, Han J, Ow R, et al. Omalizumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of asthma status. J Allergy Clin Immunol. 2020;145:AB149.","journal-title":"J Allergy Clin Immunol"},{"key":"989_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/JAA.S391896","volume":"16","author":"WW Busse","year":"2023","unstructured":"Busse WW, Pavord ID, Siddiqui S, Khan AH, Praestgaard A, Nash S, et al. Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma irrespective of baseline asthma characteristics. J Asthma Allergy. 2023;16:411\u20139.","journal-title":"J Asthma Allergy"},{"issue":"Suppl. 68","key":"989_CR26","first-page":"PA4876","volume":"64","author":"A C\u00f4t\u00e9","year":"2024","unstructured":"C\u00f4t\u00e9 A, Beach J, Reynolds J, Usuba K, Tusin J, Tehrani A, et al. OCS use in uncontrolled severe asthma in Canada. Eur Resp J. 2024;64(Suppl. 68):PA4876.","journal-title":"Eur Resp J."},{"key":"989_CR27","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23m15015","volume":"85","author":"L Kamboj","year":"2024","unstructured":"Kamboj L, Ramos B, Haynes A, Sohi G, Yang H, Ling J, et al. A retrospective observational study to understand medication utilization and lines of treatment in patients with insomnia disorder. J Clin Psychiatry. 2024;85:23m15015.","journal-title":"J Clin Psychiatry"},{"key":"989_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13223-023-00855-7","volume":"19","author":"J Silver","year":"2023","unstructured":"Silver J, Packnett E, Park J, Deb A. Biologic use and treatment patterns in patients with chronic rhinosinusitis with nasal polyps: a US real-world study. Allergy Asthma Clin Immunol. 2023;19:104.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"989_CR29","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1016\/j.jaip.2023.08.015","volume":"11","author":"G Chupp","year":"2023","unstructured":"Chupp G, Alobid I, Lugogo NL, Kariyawasam HH, Bourdin A, Chaker AM, et al. Mepolizumab reduces systemic corticosteroid use in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2023;11:3504-3512.e2.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"989_CR30","unstructured":"Canadian Agency for Drugs and Technologies in Health. Pharmacoeconomic review report Omalizumab. In: CADTH Common Drug Review. 2017. https:\/\/www.cda-amc.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/SR0457_Xolair_Resubmission_PE_Report_e.pdf. Accessed 9 June 2025."},{"key":"989_CR31","unstructured":"Canadian Agency for Drugs and Technologies in Health. Pharmacoeconomic review report Dupilumab. In: CADTH Common Drug Review. 2020. https:\/\/www.cda-amc.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/sr0636-dupixent-pharmacoeconomic-review-report.pdf. Accessed 9 June 2025."},{"key":"989_CR32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","volume":"201","author":"ER Bleecker","year":"2020","unstructured":"Bleecker ER, Menzies-Gow AN, Price DB, Bourdin A, Sweet S, Martin AL, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201:276\u201393.","journal-title":"Am J Respir Crit Care Med"},{"key":"989_CR33","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaip.2020.06.019","volume":"9","author":"TN Tran","year":"2021","unstructured":"Tran TN, MacLachlan S, Hicks W, Liu J, Chung Y, Zangrilli J, et al. Oral corticosteroid treatment patterns of patients in the United States with persistent asthma. J Allergy Clin Immunol Pract. 2021;9:338-346.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"989_CR34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","volume":"141","author":"PW Sullivan","year":"2018","unstructured":"Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141:110-116.e7.","journal-title":"J Allergy Clin Immunol"},{"key":"989_CR35","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1111\/cts.13649","volume":"16","author":"BI Wallace","year":"2023","unstructured":"Wallace BI, Tsai HJ, Lin P, Aasbjerg K, Wu AC, Tsai YF, et al. Prevalence and prescribing patterns of oral corticosteroids in the United States, Taiwan, and Denmark, 2009\u20132018. Clin Transl Sci. 2023;16:2565\u201376.","journal-title":"Clin Transl Sci"},{"key":"989_CR36","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9:1133\u201341.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"989_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290646","volume":"18","author":"S Zeitouny","year":"2023","unstructured":"Zeitouny S, Cheung DC, Bremner KE, Pataky RE, Pequeno P, Matelski J, et al. The impact of the early COVID-19 pandemic on healthcare system resource use and costs in two provinces in Canada: an interrupted time series analysis. PLoS ONE. 2023;18:e0290646.","journal-title":"PLoS ONE"},{"key":"989_CR38","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1186\/s12889-023-15658-z","volume":"23","author":"F Deslauriers","year":"2023","unstructured":"Deslauriers F, Gosselin-Boucher V, L\u00e9ger C, Vieira AM, Bacon SL, Lavoie KL. The impact of COVID-19 on the lives of Canadians with and without non-communicable chronic diseases: results from the iCARE study. BMC Public Health. 2023;23:2106.","journal-title":"BMC Public Health"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-025-00989-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-025-00989-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-025-00989-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T18:02:01Z","timestamp":1765303321000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-025-00989-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["989"],"URL":"https:\/\/doi.org\/10.1186\/s13223-025-00989-w","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is based on the analysis of de-identified patients in the IQVIA claims databases, and confidentiality of patient records was maintained at all times. Study results were in tabular form and aggregate analyses that omit subject identification. Any publications and reports will not include subject identifiers. A waiver of informed consent was not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y.C. reports relationships with GSK, Medtronic, and Sanofi for advisory boards and speaker\u2019s bureaus, and Stryker for speaker\u2019s bureaus. M\u2013N.C. reports relationships with Covis, GSK, Novartis, and Sanofi on advisory boards and speaker\u2019s bureaus. J.B. and J.R. are employed by Asthma Canada which has received funding from AstraZeneca, GSK, Novartis, Pfizer, and Sanofi, and consulting fees from Roche. K.U. and D.T. are employed by, and hold financial equities in, GSK. A.Te., J.L., and H.Y. are employed by IQVIA, which received funding from GSK for this study. A.Th. reports relationships with AstraZeneca, GSK, and Sanofi on advisory boards and speaker\u2019s bureaus in addition to consulting for Storz and Stryker.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}